Log in
Enquire now
Auspex Pharmaceuticals

Auspex Pharmaceuticals

A biopharmaceutical company that develops therapeutics to treat depressive disorders

OverviewStructured DataIssuesContributors

Contents

auspexpharma.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Healthcare
Healthcare
Chemical industry
Chemical industry
Pharmaceutical industry
Pharmaceutical industry
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Location
San Diego
San Diego
AngelList URL
angel.co/auspex-pha...maceuticals
Number of Employees (Ranges)
201 – 5000
CIK Number
1,454,1890
Place of Incorporation
Delaware
Delaware
0
Investors
Presidio Partners
Presidio Partners
0
Panorama Capital
Panorama Capital
‌
Sloan Biotech Funds
CMEA Capital
CMEA Capital
Thomas, McNerney & Partners
Thomas, McNerney & Partners
DUNS Number
0956388750
IRS Number
954,862,8420
Founded Date
2001
0
Total Funding Amount (USD)
64,992,742
Latest Funding Round Date
September 10, 2013
Latest Funding Type
Series E
Series E
CAGE Code
1Y6A30
Wellfound ID
auspex-pharmaceuticals

Other attributes

Acquirer
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries
0
SIC Code
2,8340
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Auspex Pharmaceuticals

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.